Abstract
Proteins are synthesized in heterologous systems because of the impossibility to obtain satisfactory yields from natural sources. The production of soluble and functional recombinant proteins is among the main goals in the biotechnological field. In this context, it is important to point out that under stress conditions, protein folding machinery is saturated and this promotes protein misfolding and, consequently, protein aggregation. Thus, the selection of the optimal expression organism and the most appropriate growth conditions to minimize the formation of insoluble proteins should be done according to the protein characteristics and downstream requirements.
Escherichia coli is the most popular recombinant protein expression system despite the great development achieved so far by eukaryotic expression systems. Besides, other prokaryotic expression systems, such as lactic acid bacteria and psychrophilic bacteria, are gaining interest in this field. However, it is worth mentioning that prokaryotic expression system poses, in many cases, severe restrictions for a successful heterologous protein production. Thus, eukaryotic systems such as mammalian cells, insect cells, yeast, filamentous fungus, and microalgae are an interesting alternative for the production of these difficult-to-express proteins.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anfinsen CB (1973) Principles that govern the folding of protein chains. Science 181:223–230
Mogk A, Mayer MP, Deuerling E (2002) Mechanisms of protein folding: molecular chaperones and their application in biotechnology. Chembiochem 3:807–814
Saibil H (2013) Chaperone machines for protein folding, unfolding and disaggregation. Nat Rev Mol Cell Biol 14:630–642
Hartl FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475:324–332
Bukau B, Weissman J, Horwich A (2006) Molecular chaperones and protein quality control. Cell 125:443–451
Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 10:524–530
Wetzel R (1994) Mutations and off-pathway aggregation of proteins. Trends Biotechnol 12:193–198
Fink AL (1998) Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des 3:R9–23
Speed MA, Wang DI, King J (1996) Specific aggregation of partially folded polypeptide chains: the molecular basis of inclusion body composition. Nat Biotechnol 14:1283–1287
Garcia-Mata R, Bebok Z, Sorscher EJ et al (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 146:1239–1254
Wigley WC, Fabunmi RP, Lee MG et al (1999) Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 145:481–490
Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221:3–12
Francis DM, Page R (2010) Strategies to optimize protein expression in E. coli. Curr Protoc Protein Sci. Chapter 5:Unit-29
Sorensen HP, Mortensen KK (2005) Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact 4:1
Wagner S, Klepsch MM, Schlegel S et al (2008) Tuning Escherichia coli for membrane protein overexpression. Proc Natl Acad Sci U S A 105:14371–14376
Nannenga BL, Baneyx F (2011) Reprogramming chaperone pathways to improve membrane protein expression in Escherichia coli. Protein Sci 20:1411–1420
Freigassner M, Pichler H, Glieder A (2009) Tuning microbial hosts for membrane protein production. Microb Cell Fact 8:69
Ferrer-Miralles N, Domingo-Espin J, Corchero JL et al (2009) Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 8:17
Gopal GJ, Kumar A (2013) Strategies for the production of recombinant protein in Escherichia coli. Protein J 32:419–425
Schumann W, Ferreira LCS (2004) Production of recombinant proteins in Escherichia coli. Genet Mol Biol 27:442–453
Care S, Bignon C, Pelissier M et al (2008) The translation of recombinant proteins in E-coli can be improved by in silico generating and screening random libraries of a 70/96 mRNA region with respect to the translation initiation codon. Nucleic Acids Res 36:e6
Graslund S, Nordlund P, Weigelt J et al (2008) Protein production and purification. Nat Methods 5:135–146
Hatfield G, Roth DA (2007) Optimizing scaleup yield for protein production: Computationally Optimized DNA Assembly (CODA) and Translation Engineering (TM). Biotechnol Annu Rev 13:27–42
Menzella HG (2011) Comparison of two codon optimization strategies to enhance recombinant protein production in Escherichia coli. Microb Cell Fact 10:15
Hortsch R, Weuster-Botz D (2011) Growth and recombinant protein expression with Escherichia coli in different batch cultivation media. Appl Microbiol Biotechnol 90:69–76
Sahdev S, Khattar SK, Saini KS (2008) Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies. Mol Cell Biochem 307:249–264
Apiyo D, Wittung-Stafshede P (2002) Presence of the cofactor speeds up folding of desulfovibrio desulfuricans flavodoxin. Protein Sci 11:1129–1135
Jenzsch M, Gnoth S, Kleinschmidt M et al (2007) Improving the batch-to-batch reproducibility of microbial cultures during recombinant protein production by regulation of the total carbon dioxide production. J Biotechnol 128:858–867
Song JM, An YJ, Kang MH et al (2012) Cultivation at 6–10 °C is an effective strategy to overcome the insolubility of recombinant proteins in Escherichia coli. Protein Expr Purif 82:297–301
Vaks L, Benhar I (2014) Production of stabilized scFv antibody fragments in the E. coli bacterial cytoplasm. Methods Mol Biol 34:171–184
Mollania N, Khajeh K, Ranjbar B et al (2013) An efficient in vitro refolding of recombinant bacterial laccase in Escherichia coli. Enzyme Microb Technol 52:325–330
Ramakrishnan B, Qasba PK (2013) In vitro folding of beta-1,4galactosyltransferase and polypeptide-alpha-N-acetylgalactosaminyltransferase from the inclusion bodies. Methods Mol Biol 1022:321–333 (Clifton, NJ)
Sans C, Garcia-Fruitos E, Ferraz RM et al (2012) Inclusion bodies of fuculose-1-phosphate aldolase as stable and reusable biocatalysts. Biotechnol Prog 28:421–427
Garcia-Fruitos E, Aris A, Villaverde A (2007) Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol 73:289–294
Garcia-Fruitos E, Gonzalez-Montalban N, Morell M et al (2005) Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact 4:27
Nahalka J, Mislovicova D, Kavcova H (2009) Targeting lectin activity into inclusion bodies for the characterisation of glycoproteins. Mol Biosyst 5:819–821
Nahalka J, Patoprsty V (2009) Enzymatic synthesis of sialylation substrates powered by a novel polyphosphate kinase (PPK3). Org Biomol Chem 7:1778–1780
Nahalka J (2008) Physiological aggregation of maltodextrin phosphorylase from Pyrococcus furiosus and its application in a process of batch starch degradation to alpha-D-glucose-1-phosphate. J Ind Microbiol Biotechnol 35:219–223
Peternel S, Komel R (2010) Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells. Microb Cell Fact 9:66
Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A (2007) Recombinant protein solubility – does more mean better? Nat Biotechnol 25:718–720
Peternel S, Grdadolnik J, Gaberc-Porekar V et al (2008) Engineering inclusion bodies for non denaturing extraction of functional proteins. Microb Cell Fact 7:34
Diez-Gil C, Krabbenborg S, Garcia-Fruitos E et al (2010) The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials 31:5805–5812
Liovic M, Ozir M, Zavec AB et al (2012) Inclusion bodies as potential vehicles for recombinant protein delivery into epithelial cells. Microb Cell Fact 11:67
Cano-Garrido O, Rodriguez-Carmona E, Diez-Gil C et al (2013) Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater 9:6134–6142
Villaverde A, Garcia-Fruitos E, Rinas U et al (2012) Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microb Cell Fact 11:76
Vazquez E, Corchero JL, Burgueno JF et al (2012) Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Materials 24:1742–1747
Martinez-Alonso M, Garcia-Fruitos E, Villaverde A (2008) Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng 101:1353–1358
Garcia-Fruitos E, Martinez-Alonso M, Gonzalez-Montalban N et al (2007) Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol 374:195–205
Martinez-Alonso M, Gonzalez-Montalban N, Garcia-Fruitos E et al (2008) The functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol 74:7431–7433
Garcia-Fruitos E (2012) Lactic acid bacteria: a promising alternative for recombinant protein production. Microb Cell Fact 11:157
Zweers JC, Barak I, Becher D et al (2008) Towards the development of Bacillus subtilis as a cell factory for membrane proteins and protein complexes. Microb Cell Fact 7:10
Westers L, Westers H, Quax WJ (2004) Bacillus subtilis as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism. Biochim Biophys Acta 1694:299–310
Petsch D, Anspach FB (2000) Endotoxin removal from protein solutions. J Biotechnol 76:97–119
Williams SF, Martin DP, Horowitz DM et al (1999) PHA applications: addressing the price performance issue: I. Tissue engineering. Int J Biol Macromol 25:111–121
Parlane NA, Grage K, Lee JW et al (2011) Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain. Appl Environ Microbiol 77:8516–8522
Carrio M, Gonzalez-Montalban N, Vera A et al (2005) Amyloid-like properties of bacterial inclusion bodies. J Mol Biol 347:1025–1037
Birolo L, Tutino ML, Fontanella B et al (2000) Aspartate aminotransferase from the Antarctic bacterium Pseudoalteromonas haloplanktis TAC 125. Cloning, expression, properties, and molecular modelling. Eur J Biochem 267:2790–2802
Tutino ML, Duilio A, Parrilli R et al (2001) A novel replication element from an Antarctic plasmid as a tool for the expression of proteins at low temperature. Extremophiles 5:257–264
Cusano AM, Parrilli E, Marino G et al (2006) A novel genetic system for recombinant protein secretion in the Antarctic Pseudoalteromonas haloplanktis TAC125. Microb Cell Fact 5:40
Parrilli E, Giuliani M, Marino G et al (2010) Influence of production process design on inclusion bodies protein: the case of an Antarctic flavohemoglobin. Microb Cell Fact 9:19
Duilio A, Madonna S, Tutino ML et al (2004) Promoters from a cold-adapted bacterium: definition of a consensus motif and molecular characterization of UP regulative elements. Extremophiles 8:125–132
Tutino ML, Parrilli E, Giaquinto L et al (2002) Secretion of alpha-amylase from Pseudoalteromonas haloplanktis TAB23: two different pathways in different hosts. J Bacteriol 184:5814–5817
Papa R, Rippa V, Sannia G et al (2007) An effective cold inducible expression system developed in Pseudoalteromonas haloplanktis TAC125. J Biotechnol 127:199–210
Parrilli E, De VD, Cirulli C et al (2008) Development of an improved Pseudoalteromonas haloplanktis TAC125 strain for recombinant protein secretion at low temperature. Microb Cell Fact 7:2
Dragosits M, Frascotti G, Bernard-Granger L et al (2011) Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. Biotechnol Prog 27:38–46
Giuliani M, Parrilli E, Ferrer P et al (2011) Process optimization for recombinant protein production in the psychrophilic bacterium Pseudoalteromonas haloplanktis. Process Biochem 46:953–959
Vigentini I, Merico A, Tutino ML et al (2006) Optimization of recombinant human nerve growth factor production in the psychrophilic Pseudoalteromonas haloplanktis. J Biotechnol 127:141–150
Rattenholl A, Lilie H, Grossmann A et al (2001) The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem 268:3296–3303
Piette F, D’Amico S, Struvay C et al (2010) Proteomics of life at low temperatures: trigger factor is the primary chaperone in the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125. Mol Microbiol 76:120–132
Wilmes B, Hartung A, Lalk M et al (2010) Fed-batch process for the psychrotolerant marine bacterium Pseudoalteromonas haloplanktis. Microb Cell Fact 9:72
Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393–1398
Figueroa B Jr, Ailor E, Osborne D et al (2007) Enhanced cell culture performance using inducible anti-apoptotic genes E1B-19K and Aven in the production of a monoclonal antibody with Chinese hamster ovary cells. Biotechnol Bioeng 97:877–892
Geisse S (2009) Reflections on more than 10 years of TGE approaches. Protein Expr Purif 64:99–107
Derouazi M, Girard P, Van TF et al (2004) Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng 87:537–545
Rosser MP, Xia W, Hartsell S et al (2005) Transient transfection of CHO-K1-S using serum-free medium in suspension: a rapid mammalian protein expression system. Protein Expr Purif 40:237–243
Baldi L, Hacker DL, Adam M et al (2007) Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 29:677–684
Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9
Girard P, Derouazi M, Baumgartner G et al (2002) 100-liter transient transfection. Cytotechnology 38:15–21
Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 143:1883–1898
Kopito RR, Sitia R (2000) Aggresomes and Russell bodies. Symptoms of cellular indigestion? EMBO Rep 1:225–231
Zaarur N, Meriin AB, Gabai VL et al (2008) Triggering aggresome formation. Dissecting aggresome-targeting and aggregation signals in synphilin 1. J Biol Chem 283:27575–27584
Garcia-Mata R, Gao YS, Sztul E (2002) Hassles with taking out the garbage: aggravating aggresomes. Traffic 3:388–396
Shimohata T, Sato A, Burke JR et al (2002) Expanded polyglutamine stretches form an ‘aggresome’. Neurosci Lett 323:215–218
Kim MC, Song J, Min O et al (2013) Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 21:485–492
Loureiro S, Ren J, Phapugrangkul P et al (2011) Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J Virol 85:3010–3014
Huetter J, Roedig JV, Hoeper D et al (2013) Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J Immunol 190:220–230
De Groot AS, Scott DW (2007) Immunogenicity of protein therapeutics. Trends Immunol 28:482–490
Legardinier S, Duoner-Cerutti M, Devauchelle G et al (2005) Biological activities of recombinant equine luteinizing hormone/chorionic gonadotropin (eLH/CG) expressed in Sf9 and Mimic insect cell lines. J Mol Endocrinol 34:47–60
Radner S, Celie PH, Fuchs K et al (2012) Transient transfection coupled to baculovirus infection for rapid protein expression screening in insect cells. J Struct Biol 179:46–55
Heath CM, Windsor M, Wileman T (2001) Aggresomes resemble sites specialized for virus assembly. J Cell Biol 153:449–455
Bernard A, Payton M, Radford KR (2001) Protein expression in the baculovirus system. Curr Protoc Neurosci. Chapter 4:Unit 4.19
Martinez-Alonso M, Toledo-Rubio V, Noad R et al (2009) Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol 75:7850–7854
Ardiani A, Higgins JP, Hodge JW (2010) Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Res 10:1060–1069
Evans L, Hughes M, Waters J, et al. (2010) The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. Protein Expr Purif. 73(2): 113–124
Kim BJ, Zhou J, Martin B, et al. (2010) Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther. 334(3): 682–692
Chiba Y, Akeboshi H (2009) Glycan engineering and production of ‘humanized’ glycoprotein in yeast cells. Biol Pharm Bull 32:786–795
Gerngross TU (2004) Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22:1409–1414
Nakayama K, Nagasu T, Shimma Y et al (1992) OCH1 encodes a novel membrane bound mannosyltransferase: outer chain elongation of asparagine-linked oligosaccharides. EMBO J 11:2511–2519
Gasser B, Saloheimo M, Rinas U et al (2008) Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact 7:11
Porro D, Sauer M, Branduardi P et al (2005) Recombinant protein production in yeasts. Mol Biotechnol 31:245–259
Porro D, Branduardi P (2009) Yeast cell factory: fishing for the best one or engineering it? Microb Cell Fact 8:51
Ciplys E, Samuel D, Juozapaitis M et al (2011) Overexpression of human virus surface glycoprotein precursors induces cytosolic unfolded protein response in Saccharomyces cerevisiae. Microb Cell Fact 10:37
Boer E, Steinborn G, Kunze G et al (2007) Yeast expression platforms. Appl Microbiol Biotechnol 77:513–523
Cregg JM, Cereghino JL, Shi J et al (2000) Recombinant protein expression in Pichia pastoris. Mol Biotechnol 16:23–52
Li P, Anumanthan A, Gao XG et al (2007) Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol 142:105–124
Shekhar C (2008) Pichia power: India’s biotech industry puts unconventional yeast to work. Chem Biol 15:201–202
Rabert C, Weinacker D, Pessoa A et al (2013) Recombinants proteins for industrial uses: utilization of Pichia pastoris expression system. Braz J Microbiol 44:351–356
Gasser B, Prielhofer R, Marx H et al (2009) Pichia pastoris: protein production host and model organism for biomedical research. Future Microbiol 8:191–208
Bollok M, Resina D, Valero F et al (2009) Recent patents on the Pichia pastoris expression system: expanding the toolbox for recombinant protein production. Recent Pat Biotechnol 3:192–201
Graf A, Gasser B, Dragosits M et al (2008) Novel insights into the unfolded protein response using Pichia pastoris specific DNA microarrays. BMC Genomics 9:390
Cherry JR, Fidantsef AL (2003) Directed evolution of industrial enzymes: an update. Curr Opin Biotechnol 14:438–443
Harkki A, Uusitalo J, Bailey M et al (1989) A novel fungal expression system – secretion of active calf chymosin from the filamentous fungus Trichoderma reesei. Nat Biotechnol 7:596–603
Stals I, Sandra K, Devreese B et al (2004) Factors influencing glycosylation of Trichoderma reesei cellulases. II: N-glycosylation of Cel7A core protein isolated from different strains. Glycobiology 14:725–737
Stals I, Sandra K, Geysens S et al (2004) Factors influencing glycosylation of Trichoderma reesei cellulases. I: Postsecretorial changes of the O- and N-glycosylation pattern of Cel7A. Glycobiology 14:713–724
Maras M, De Bruyn A, Vervecken W et al (1999) In vivo synthesis of complex N-glycans by expression of human N-acetylglucosaminyltransferase I in the filamentous fungus Trichoderma reesei. FEBS Lett 452:365–370
Saloheimo M, Lund M, Penttila ME (1999) The protein disulphide isomerase gene of the fungus Trichoderma reesei is induced by endoplasmic reticulum stress and regulated by the carbon source. Mol Gen Genet 262:35–45
Collen A, Saloheimo M, Bailey M et al (2005) Protein production and induction of the unfolded protein response in Trichoderma reesei strain Rut-C30 and its transfor-mant expressing endoglucanase I with a hydrophobic tag. Biotechnol Bioeng 89:335–344
Spolaore P, Joannis-Cassan C, Duran E et al (2006) Commercial applications of microalgae. J Biosci Bioeng 101:87–96
Apt KE, Behrens PW (1999) Commercial developments in microalgal biotechnology. J Phycol 35:215–226
Walker TL, Purton S, Becker DK et al (2005) Microalgae as bioreactors. Plant Cell Rep 24:629–641
Specht E, Miyake-Stoner S, Mayfield S (2010) Micro-algae come of age as a platform for recombinant protein production. Biotechnol Lett 32:1373–1383
Gong Y, Hu H, Gao Y et al (2011) Microalgae as platforms for production of recombinant proteins and valuable compounds: progress and prospects. J Ind Microbiol Biotechnol 38:1879–1890
Janssen M, Tramper J, Mur LR et al (2003) Enclosed outdoor photobioreactors: light regime, photosynthetic efficiency, scale-up, and future prospects. Biotechnol Bioeng 81:193–210
Mayfield SP, Franklin SE, Lerner RA (2003) Expression and assembly of a fully active antibody in algae. Proc Natl Acad Sci U S A 100:438–442
Griesbeck C, Kobl I, Heitzer M (2006) Chlamydomonas reinhardtii: a protein expression system for pharmaceutical and biotechnological proteins. Mol Biotechnol 34:213–223
Rosenberg JN, Oyler GA, Wilkinson L et al (2008) A green light for engineered algae: redirecting metabolism to fuel a biotechnology revolution. Curr Opin Biotechnol 19:430–436
Boynton JE, Gillham NW, Harris EH et al (1988) Chloroplast transformation in Chlamydomonas with high velocity microprojectiles. Science 240:1534–1538
Debuchy R, Purton S, Rochaix JD (1989) The argininosuccinate lyase gene of Chlamydomonas reinhardtii: an important tool for nuclear transformation and for correlating the genetic and molecular maps of the ARG7 locus. EMBO J 8:2803–2809
Fernandez E, Schnell R, Ranum LP et al (1989) Isolation and characterization of the nitrate reductase structural gene of Chlamydomonas reinhardtii. Proc Natl Acad Sci U S A 86:6449–6453
Mayfield SP, Schultz J (2004) Development of a luciferase reporter gene, luxCt, for Chlamydomonas reinhardtii chloroplast. Plant J 37:449–458
Franklin S, Ngo B, Efuet E et al (2002) Development of a GFP reporter gene for Chlamydomonas reinhardtii chloroplast. Plant J 30:733–744
Barnes D, Franklin S, Schultz J et al (2005) Contribution of 5′- and 3′-untranslated regions of plastid mRNAs to the expression of Chlamydomonas reinhardtii chloroplast genes. Mol Genet Genomics 274:625–636
Potvin G, Zhang Z (2010) Strategies for high-level recombinant protein expression in transgenic microalgae: a review. Biotechnol Adv 28:910–918
Franklin SE, Mayfield SP (2005) Recent developments in the production of human therapeutic proteins in eukaryotic algae. Expert Opin Biol Ther 5:225–235
Grayson WL, Martens TP, Eng GM et al (2009) Biomimetic approach to tissue engineering. Semin Cell Dev Biol 20:665–673
Boehm R (2007) Bioproduction of therapeutic proteins in the 21st century and the role of plants and plant cells as production platforms. Ann N Y Acad Sci 1102:121–134
Weathers PJ, Towler MJ, Xu J (2010) Bench to batch: advances in plant cell culture for producing useful products. Appl Microbiol Biotechnol 85:1339–1351
Li SS, Tsai HJ (2009) Transgenic microalgae as a non-antibiotic bactericide producer to defend against bacterial pathogen infection in the fish digestive tract. Fish Shellfish Immunol 26:316–325
Joensuu JJ, Conley AJ, Linder MB et al (2012) Bioseparation of recombinant proteins from plant extract with hydrophobin fusion technology. Methods Mol Biol 824:527–534
Tian L, Sun SS (2011) A cost-effective ELP-intein coupling system for recombinant protein purification from plant production platform. PLoS One 6:e24183
Torrent M, Llop-Tous I, Ludevid M (2009) Protein body induction: a new tool to produce and recover recombinant proteins in plants. Methods Mol Biol 483:193–208
Wilken LR, Nikolov ZL (2012) Recovery and purification of plant-made recombinant proteins. Biotechnol Adv 30:419–433
Torrent M, Llompart B, Lasserre-Ramassamy S et al (2009) Eukaryotic protein production in designed storage organelles. BMC Biol 7:5
Katzen F, Chang G, Kudlicki W (2005) The past, present and future of cell-free protein synthesis. Trends Biotechnol 23:150–156
Swartz J (2006) Developing cell-free biology for industrial applications. J Ind Microbiol Biotechnol 33:476–485
Carlson ED, Gan R, Hodgman CE et al (2012) Cell-free protein synthesis: applications come of age. Biotechnol Adv 30:1185–1194
Endo Y, Sawasaki T (2006) Cell-free expression systems for eukaryotic protein production. Curr Opin Biotechnol 17:373–380
Dadashipour M, Fukuta Y, Asano Y (2011) Comparative expression of wild-type and highly soluble mutant His103Leu of hydroxynitrile lyase from Manihot esculenta in prokaryotic and eukaryotic expression systems. Protein Expr Purif 77:92–97
Kudou M, Ejima D, Sato H et al (2011) Refolding single-chain antibody (scFv) using lauroyl-L-glutamate as a solubilization detergent and arginine as a refolding additive. Protein Expr Purif 77:68–74
Shimizu Y, Inoue A, Tomari Y et al (2001) Cell-free translation reconstituted with purified components. Nat Biotechnol 19:751–755
Shimizu Y, Kanamori T, Ueda T (2005) Protein synthesis by pure translation systems. Methods 36:299–304
Spirin AS, Baranov VI, Ryabova LA et al (1988) A continuous cell-free translation system capable of producing polypeptides in high yield. Science 242:1162–1164
Kim DM, Choi CY (1996) A semicontinuous prokaryotic coupled transcription/translation system using a dialysis membrane. Biotechnol Prog 12:645–649
Kigawa T, Yabuki T, Yoshida Y et al (1999) Cell-free production and stable-isotope labeling of milligram quantities of proteins. FEBS Lett 442:15–19
Yamamoto YI, Nagahori H, Yao SL et al (1996) Hollow fiber reactor for continuous flow cell-free protein production. J Chem Eng Jpn 29:1047–1050
Kawarasaki Y, Nakano H, Yamane T (1994) Prolonged cell-free protein synthesis in a batch system using wheat germ extract. Biosci Biotechnol Biochem 58:1911–1913
Kawarasaki Y, Kawai T, Nakano H et al (1995) A long-lived batch reaction system of cell-free protein synthesis. Anal Biochem 226:320–324
Jewett MC, Swartz JR (2004) Rapid expression and purification of 100 nmol quantities of active protein using cell-free protein synthesis. Biotechnol Prog 20:102–109
Garcia-Fruitos E, Sabate R, de Groot NS et al (2011) Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J 278:2419–2427
Wang L (2009) Towards revealing the structure of bacterial inclusion bodies. Prion 3:139–145
Mitraki A (2010) Protein aggregation from inclusion bodies to amyloid and biomaterials. Adv Protein Chem Struct Biol 79:89–125
Doi H, Mitsui K, Kurosawa M et al (2004) Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett 571:171–176
Suhr ST, Senut MC, Whitelegge JP et al (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol 153:283–294
Zhang X, Qian SB (2011) Chaperone-mediated hierarchical control in targeting misfolded proteins to aggresomes. Mol Biol Cell 22:3277–3288
Beaudoin S, Goggin K, Bissonnette C et al (2008) Aggresomes do not represent a general cellular response to protein misfolding in mammalian cells. BMC Cell Biol 9:59
Tanaka M, Kim YM, Lee G et al (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279:4625–4631
Wang Y, Meriin AB, Costello CE et al (2007) Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders. Prion 1:128–135
Meriin AB, Wang Y, Sherman MY (2010) Isolation of aggresomes and other large aggregates. Curr Protoc Cell Biol. Chapter 3:Unit-9
Calo-Fernandez B, Martinez-Hurtado JL (2012) Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals 5:1393–1408
Weinacker D, Rabert C, Zepeda AB et al (2013) Applications of recombinant in the healthcare industry. Braz J Microbiol 44:1043–1048
Demain AL, Vaishnav P (2009) Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 27:297–306
Brondyk WH (2009) Selecting an appropriate method for expressing a recombinant protein. Methods Enzymol 463:131–147
Chen R (2012) Bacterial expression systems for recombinant protein production: E. coli and beyond. Biotechnol Adv 30:1102–1107
Grillberger L, Kreil TR, Nasr S et al (2009) Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 4:186–201
Berkowitz SA, Engen JR, Mazzeo JR et al (2012) Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 11:527–540
Lebendiker M, Danieli T (2014) Production of prone-to-aggregate proteins. FEBS Lett 588:236–246
Acknowledgments
The authors acknowledge the financial support granted to E.G.F. from Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria—MINECO (RTA2012-00028-C02-02) and Centro de Investigación Biomédica en Red (CIBER) de Bioingeniería, Biomateriales y Nanomedicina. Z.X. acknowledges financial support from China Scholarship Council. PS has received a predoctoral fellowship from Instituto de Salud Carlos III. The authors are also indebted to the Protein Production Platform (CIBER-BBN—UAB) for helpful technical assistance (http://www.bbn.ciber-bbn.es/programas/plataformas/equipamiento).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Ferrer-Miralles, N., Saccardo, P., Corchero, J.L., Xu, Z., García-Fruitós, E. (2015). General Introduction: Recombinant Protein Production and Purification of Insoluble Proteins. In: García-Fruitós, E. (eds) Insoluble Proteins. Methods in Molecular Biology, vol 1258. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2205-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2205-5_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2204-8
Online ISBN: 978-1-4939-2205-5
eBook Packages: Springer Protocols